While much of the public health conversation in Brazil has focused on the seasonal rise of Influenza A, medical experts are warning that another respiratory threat is quietly escalating. Data from the Ministério da Saúde reveals that in the first quarter of this year, 18% of confirmed cases of Severe Acute Respiratory Syndrome (SRAG) were caused by the Respiratory Syncytial Virus (RSV), known in Brazil as VSR.
Long dismissed as a pediatric ailment primarily responsible for bronchiolitis in infants, the virus is proving far more dangerous for the elderly than previously understood. The risk is compounded by a critical gap in diagnostic testing and a general lack of public awareness regarding how the virus affects adults over 50.
The prevalence of the virus has shown a steady climb. According to the Infogripe Bulletin from the Oswaldo Cruz Foundation (Fiocruz), VSR accounted for 14% of confirmed viral syndromes between February and March, a figure that rose to 19.9% by April. The trend is even more pronounced in private laboratory data; in the week ending April 4, 38% of all positive viral tests were for VSR, marking a 12-point increase from the first week of March.
The ‘Iceberg’ Effect in Adult Diagnostics
The official numbers may only represent a fraction of the actual burden. Rosemeri Maurici, a pneumologist and professor at the Federal University of Santa Catarina (UFSC), describes the current data as the “tip of the iceberg.” She notes that large-scale testing for VSR in Brazil only became common during the COVID-19 pandemic, leaving a significant void in the historical understanding of the virus’s impact on adults.
A primary driver of this underreporting is the biological window for detection. In adults, the viral load of VSR drops significantly after 72 hours of infection, making the virus difficult to detect if the patient is tested late. In contrast, infants retain the virus longer, creating a wider diagnostic window that skews statistics toward the pediatric population.
“Muitos hospitais internam pacientes com síndrome respiratória aguda agrave, e eles até morrem, sem saber qual o agente que causou, porque não testaram ou testaram fora do prazo que é identificável.”
The scale of this diagnostic gap is evident in the first-quarter SRAG figures: of approximately 27,600 registered cases, only 9,079 had an identified viral cause. Nearly 17% of patients were not tested at all, suggesting that many elderly patients may be succumbing to VSR without a formal diagnosis.
Why the Elderly Are More Vulnerable
The intersection of aging and chronic illness creates a “perfect storm” for VSR complications. Geriatrician Maisa Kairalla points to immunosenescence—the natural decline of the immune system as people age—which increases susceptibility to infectious diseases. In Brazil, What we have is often exacerbated by a high prevalence of chronic comorbidities and a history of smoking or alcohol use.
The clinical outcomes for seniors with VSR are significantly more severe than those with influenza. According to medical literature presented by Kairalla, an elderly patient with VSR is 2.7 times more likely to develop pneumonia and twice as likely to require intubation in an ICU or die compared to a patient with influenza.
| Patient Group | Primary Risk/Complication | Clinical Impact |
|---|---|---|
| Cardiovascular Patients | Systemic inflammation | >60% of severe VSR cases involve heart disease |
| Diabetic Patients | High blood glucose | Increased susceptibility to severe infection |
| Chronic Respiratory (DPOC/Asthma) | Accelerated lung function loss | 70% increase in 3-year mortality after ICU stay |
| General Elderly (65+) | Immunosenescence | 2x higher ICU/death risk vs. Influenza |
The systemic nature of the infection is particularly dangerous for those with heart conditions. Múcio Tavares, a cardiologist and professor at the University of São Paulo (USP), explains that viral respiratory infections trigger systemic inflammation, which can lead to myocardial infarction, stroke, or a worsening of heart failure.
Similarly, endocrinologist Rodrigo Mendes warns that diabetes patients are highly vulnerable. Even those with stable control can experience an exacerbated inflammatory response upon contracting VSR, necessitating complex hospitalization and intensive care.
The Path to Prevention and Public Policy
While the risk is high, VSR is preventable through vaccination. However, access in Brazil is currently bifurcated. The National Immunization Program (PNI) via the SUS currently provides the vaccine only for pregnant women to protect newborns. For the adult population, vaccines are available exclusively through private healthcare providers.
Medical organizations, including the Brazilian Society of Immunizations (Sbim), recommend the vaccine for individuals aged 50 to 69 with comorbidities and for all adults aged 70 and older. Professor Maurici, who also coordinates the Immunization Commission of the Brazilian Society of Pneumology and Tisiology, is urging medical societies to formally recommend these priority groups to Conitec, the body responsible for advising the Ministry of Health on incorporating new therapies into the public system.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
The next critical step for public health advocates is the formal submission of priority group data to Conitec to potentially expand public access to the vaccine. As the second quarter progresses, health authorities are expected to monitor whether the upward trend in VSR cases continues to mirror the patterns seen in previous years.
Do you or a family member have concerns about respiratory health this season? Share your thoughts or questions in the comments below.
Related reading
